Auregen Bio raises €47.8M Growth round

1 December 2016· Geneva, Switzerland· health, biotechnology, bioprinting, cell_therapy, software_hardware, b2b

The funding was for a company offering various biotechnology solutions, including an intellectual property platform for 3D bioprinting and creating new treatment options for patients with rare congenital craniofacial disorders.